StreetInsider.com News Articles

Piper Sandler on Kestra Medical Technologies (KMTS): 'We remain highly bullish on the name'

Mon, 05 Oct 2026 08:46:22 -0400

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $30.00 price target on Kestra Medical Technologies (NASDAQ: KMTS).

The analyst commented: "Kestra’s Patents Point to Wearable Pacing As Its Next Platform Extension; Recently, Kestra management disclosed a late-stage R&D project, but provided little detail on the technology or potential opportunity. We dug into Kestra’s patent portfolio and believe the evidence points toward a pacing-enabled WCD as the potential next major platform extension. We believe post-TAVR patients represent the clearest potential opportunity (but there are other applications too), which we estimate could represent a $70M annual market though reimbursement remains an

Form 4 KESTRA MEDICAL TECHNOLOG For: Sep 30 Filed by: COHEN RAYMOND W

Thu, 01 Oct 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27137478.html

Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies

Thu, 01 Oct 2026 06:00:00 -0400

KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek’s list of America’s Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.

“In less than a decade, our team brought the ASSURE® WCD to market and built a rapidly growing commercial business, giving clinicians a differentiated choice for protecting patients during periods of cardiac risk

Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies

Thu, 01 Oct 2026 06:00:00 -0400

Form 144 KESTRA MEDICAL TECHNOLOG Filed by: COHEN RAYMOND W

Wed, 30 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260930/27128706.html

Raymond W. Cohen named chairman of CAIRDAC board of directors

Thu, 24 Sep 2026 03:49:14 -0400

CAIRDAC, a French medical technology company developing a leadless, self-powered cardiac pacemaker, announced the appointment of Raymond W. Cohen as chairman of its board of directors.

Cohen has more than four decades of medical technology industry experience. He co-founded and served as chief executive of Axonics, Inc. (Nasdaq: AXNX), a maker of implantable neuromodulation devices that held its initial public offering in 2018 and was acquired by Boston Scientific in late 2024 for $3.7 billion. In 2025, Cohen, as chairman of SoniVie, Ltd., led the sale of that company for $600 million, and later that year led the sale of Nalu

Raymond W. Cohen named chairman of CAIRDAC board of directors

Thu, 24 Sep 2026 03:49:14 -0400

CAIRDAC, a French medical technology company developing a leadless, self-powered cardiac pacemaker, announced the appointment of Raymond W. Cohen as chairman of its board of directors.

CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors

Thu, 24 Sep 2026 03:49:00 -0400

ANTONY, France--(BUSINESS WIRE)-- CAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board of directors.

“We are thrilled to welcome Mr. Cohen to the CAIRDAC board of directors,” said Edouard Fonck, Chief Executive Officer of CAIRDAC, “Ray’s extensive track record in leading, scaling and exiting medical technology companies will, no doubt, be invaluable as we advance this exciting project.”

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience.

CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors

Thu, 24 Sep 2026 03:49:00 -0400

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience.

CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors

Thu, 24 Sep 2026 03:49:00 -0400

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience.

CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors

Thu, 24 Sep 2026 03:49:00 -0400

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience.

Form 4 KESTRA MEDICAL TECHNOLOG For: Sep 21 Filed by: Kwo Elizabeth

Wed, 23 Sep 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260923/27097568.html

Form 144 KESTRA MEDICAL TECHNOLOG Filed by: Kwo Elizabeth

Mon, 21 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260921/27085308.html

Piper Sandler on Kestra Medical Technologies (KMTS): 'Buy The Dip on Leverage Concerns'

Tue, 15 Sep 2026 11:01:17 -0400

Piper Sandler analyst Matt O\'Brien reiterated an Overweight rating and $30.00 price target on Kestra Medical Technologies (NASDAQ: KMTS).

The analyst commented: "Strong FQ1 & Guidance Moves Higher; Buy The Dip on Leverage Concerns; This afternoon, KMTS reported strong FQ1 results with a top-line beat and solid GM. Sales guidance for fiscal '27 was raised, and while it implies a steep back half of the year, we believe it is achievable given strong market growth, increasing covered lives, and improving sales rep productivity. Management also increased its intermediate (next 2-3 years) GM outlook to the mid-70% range (up from the low

Kestra Medical Technologies (KMTS) Reiterated at Buy by Stifel as Sales Guidance Raised

Tue, 15 Sep 2026 06:59:50 -0400

Stifel analyst Rick Wise reiterated a Buy rating and $30.00 price target on Kestra Medical Technologies (NASDAQ: KMTS).

The analyst commented, "Kestra kicked off the F2027 year (ending April 2027) positively, delivering better-than-expected top-line and gross margin performance. At the same time, the company raised full-year sales guidance by more than the F1Q27 sales beat. In the quarter, KMTS reported revenue of $31.0M (+60% y/y), which exceeded our/Consensus $29.0M estimate by roughly $2M. Management highlighted that the quarter's impressive +60% growth was driven by multiple factors including accelerated WCD market growth, competitive share gains, sales territory expansion, and revenue conversion rate

Form 10-Q KESTRA MEDICAL TECHNOLOG For: Jul 31

Mon, 14 Sep 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260914/27059321.html

Form 8-K KESTRA MEDICAL TECHNOLOG For: Sep 14

Mon, 14 Sep 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260914/27058342.html

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh

Mon, 14 Sep 2026 16:04:00 -0400

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) reported Q1 EPS of ($0.75), versus ($0.50) reported last year. Revenue for the quarter came in at $30.97 million, versus $19.37 million reported last year.

GUIDANCE:

Kestra Medical Technologies, Ltd. sees FY2026 revenue of $141 billion.

For earnings history and earnings-related data on Kestra Medical Technologies, Ltd. (KMTS) click here.

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh

Mon, 14 Sep 2026 16:04:00 -0400

GUIDANCE:

Kestra Medical Technologies, Ltd. sees FY2026 revenue of $141 billion.

For earnings history and earnings-related data on Kestra Medical Technologies, Ltd. (KMTS) click here.

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

Mon, 14 Sep 2026 16:01:00 -0400

KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.

Financial Highlights

Generated revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.
Expanded gross margin to 56.5% in F1Q27 compared to 45.7% in the prior year period.
Increased FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26.

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

Mon, 14 Sep 2026 16:01:00 -0400

Financial Highlights

Generated revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.
Expanded gross margin to 56.5% in F1Q27 compared to 45.7% in the prior year period.
Increased FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26.

Form 4 KESTRA MEDICAL TECHNOLOG For: Sep 08 Filed by: Schwartz Jeffrey Lawrence

Thu, 10 Sep 2026 20:44:00 -0400

si-local-file:///var/storage/secattach/20260910/27049838.html

Form 4 KESTRA MEDICAL TECHNOLOG For: Sep 09 Filed by: Kwo Elizabeth

Thu, 10 Sep 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260910/27049824.html

Form 4 KESTRA MEDICAL TECHNOLOG For: Sep 09 Filed by: COHEN RAYMOND W

Thu, 10 Sep 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260910/27049822.html

Form 4 KESTRA MEDICAL TECHNOLOG For: Sep 08 Filed by: Hanley Conor

Thu, 10 Sep 2026 20:28:00 -0400

si-local-file:///var/storage/secattach/20260910/27049814.html